Nasal Vaccination with β-Amyloid Peptide for the Treatment of Alzheimer's Disease

Alzheimer's disease (AD) is a severe neurodegenerative disease for which there is currently no effective prevention or treatment. The prediction that the number of U.S. patients with AD will triple...

[1]  D. Selkoe,et al.  Immune hyporesponsiveness to amyloid β-peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  B Frangione,et al.  Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. , 2001, The American journal of pathology.

[3]  David J. Cummins,et al.  Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Brian J. Bacskai,et al.  Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy , 2001, Nature Medicine.

[5]  J. Hardy,et al.  Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.

[6]  Ralph A. Nixon,et al.  Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.

[7]  D. Selkoe,et al.  Nasal Aβ Treatment Induces Anti‐Aβ Antibody Production and Decreases Cerebral Amyloid Burden in PD‐APP Mice , 2000 .

[8]  B. Solomon,et al.  Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[9]  D. Selkoe,et al.  Nasal administration of amyloid‐β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease , 2000, Annals of neurology.

[10]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[11]  D. Selkoe,et al.  Nasal Aβ immunization reduces amyloid-β protein burden in PDAPP mice , 2000, Neurobiology of Aging.

[12]  F. Oftung,et al.  Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine. , 2000, Vaccine.

[13]  J. Ward,et al.  Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. , 2000, Vaccine.

[14]  R. Rappuoli,et al.  Mutants of Escherichia coli Heat-Labile Toxin Act as Effective Mucosal Adjuvants for Nasal Delivery of an Acellular Pertussis Vaccine: Differential Effects of the Nontoxic AB Complex and Enzyme Activity on Th1 and Th2 Cells , 1999, Infection and Immunity.

[15]  R. Glück,et al.  Phase 1 Evaluation of Intranasal Virosomal Influenza Vaccine with and without Escherichia coli Heat-Labile Toxin in Adult Volunteers , 1999, Journal of Virology.

[16]  R. Rappuoli,et al.  Mucosal delivery of vaccines. , 1999, Methods.

[17]  G. Ott,et al.  Intranasal Immunization of Mice with Influenza Vaccine in Combination with the Adjuvant LT-R72 Induces Potent Mucosal and Serum Immunity Which Is Stronger than That with Traditional Intramuscular Immunization , 1999, Infection and Immunity.

[18]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[19]  T. Ben-Yedidia,et al.  Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection. , 1999, International immunology.

[20]  P. Mayeux,et al.  Effectiveness of a Vaccine Composed of Heat-Killed Candida albicans and a Novel Mucosal Adjuvant, LT(R192G), against Systemic Candidiasis , 1999, Infection and Immunity.

[21]  H. Davis,et al.  CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. , 1998, Journal of immunology.

[22]  J. Clements,et al.  LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp. , 1998, Vaccine.

[23]  J. Mascola,et al.  HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. , 1998, Journal of immunology.

[24]  A. Krieg,et al.  CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. , 1998, Journal of immunology.

[25]  T. Kurata,et al.  Effects of frequent intranasal administration of adjuvant-combined influenza vaccine on the protection against virus infection. , 1997, Vaccine.

[26]  M. Noda,et al.  A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. Solomon,et al.  Disaggregation of Alzheimer β-amyloid by site-directed mAb , 1997 .

[28]  M. Marinaro,et al.  Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. , 1996, The Journal of infectious diseases.

[29]  Christopher C. Goodnow,et al.  C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity , 1996, Science.

[30]  B. Solomon,et al.  Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Clements,et al.  Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity , 1995, Infection and immunity.

[32]  G. Dougan,et al.  Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  S. Langermann,et al.  Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi , 1994, Nature.

[34]  J. Biewenga,et al.  The role of nasopharyngeal lymphoid tissue. , 1992, Immunology today.

[35]  S. Falkow,et al.  Amino acid sequence homology between cholera toxin and Escherichia coli heat-labile toxin , 1980, Nature.

[36]  N. Pierce,et al.  Cellular kinetics of the intestinal immune response to cholera toxoid in rats , 1975, The Journal of experimental medicine.